Propiverine Hydrochloride, FCT

Propiverine Hydrochloride, FCT
Product Description

Pharmaceutical Licensing Product
Chemical for urinary incontinence

Aenova offers a broad range of pharmaceutical license products under the following license model:

  • Aenova provides and updates dossiers and scientific material 
  •  Licensee prepares dossier according to the local requirements and files for MA-approval 
  •  Aenova manufactures and supplies finished product 
  •  Licensee markets and sells the product in its territory

Aenova Holding GmbH

  • DE
  • 2015
    On CPhI since

Aenova Holding GmbH

  • DE
  • 2015
    On CPhI since

More Products from Aenova Holding GmbH

  • Diclofenac / Omeprazole, HGC, modified release

    Product Diclofenac / Omeprazole, HGC, modified release

    Pharmaceutical Licensing Product
    Chemical for symptomatic treatment of RA, osteoarthritis, ankylosing spondylitis

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material 
    •  Licensee prepares dossier according to the local requirements and files for MA-approval 
    •  Aenova manufactures and supplies finished product 
    •  Licensee markets and sells the product in its territory
  • Ethinylestradiol / Levonorgestrel, SCT

    Product Ethinylestradiol / Levonorgestrel, SCT

    Pharmaceutical Licensing Product
    Chemical for oral contraception (2nd generation)

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material 
    •  Licensee prepares dossier according to the local requirements and files for MA-approval 
    •  Aenova manufactures and supplies finished product 
    •  Licensee markets and sells the product in its territory
  • Diclofenac Dual Release, HGC

    Product Diclofenac Dual Release, HGC

    Pharmaceutical Licensing Product
    Chemical for pain and inflammation

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material 
    •  Licensee prepares dossier according to the local requirements and files for MA-approval 
    •  Aenova manufactures and supplies finished product 
    •  Licensee markets and sells the product in its territory
  • Horse Chestnut Seeds Extract, HGC, Cream or Ointment

    Product Horse Chestnut Seeds Extract, HGC, Cream or Ointment

    Pharmaceutical Licensing Product
    Herbal for venous insufficiency

    Aenova offers a broad range of pharmaceutical license products under the following license model:
    • Aenova provides and updates dossiers and scientific material 
    •  Licensee prepares dossier according to the local requirements and files for MA-approval 
    •  Aenova manufactures and supplies finished product 
    •  Licensee markets and sells the product in its territory
  • Vegapure® Emulsorb, SGC

    Product Vegapure® Emulsorb, SGC

    Consumer Health Care Product Concept
    Cholesterol control

    Aenova offers broad expertise in the development of Consumer Health Care products:
    • Thorough understanding of global and regional market needs 
    • Creation of new product concepts based on current and foreseen innovation trends 
    • Strong support to ensure regulatory compliance 
    • Providing comprehensive quality and scientific documentations
  • Metformin Hydrochloride, FCT

    Product Metformin Hydrochloride, FCT

    Pharmaceutical Licensing Product
    Chemical for diabetes type II


    Aenova offers a broad range of pharmaceutical license products under the following license model: 
    • Aenova provides and updates dossiers and scientific material   
    • Licensee prepares dossier according to the local requirements and files for MA-approval   
    • Aenova manufactures and supplies finished product   
    • Licensee markets and sells the product in its territory  

Aenova Holding GmbH resources

  • Brochure Aenova publishes Annual Report 2020

    Aenova publishes its 2020 Annual Report today. The report summarises the business and highlights for 2020 and gives insights into the company’s strategy.

    Learn more about Aenova's 2020 achievements and milestones, as well as key events in each business unit

  • Brochure Production Expansion at Aenova Tittmoning

    We make the advantages of continuous production available to you. That is why we have invested in our „Enterprise Concept“ and greatly increased production capacity.

    Increased production capacity to over 10 billion tablets per year at Aenova Tittmoning࡟Investment of about € 25 million as one of the strategic growth projects
    ࡟More than 3,100 sqm large production building is being constructed
    ࡟With 700 employees, the Tittmoning site will produce 10 billion tablets for more than 100 customers on all continents
  • Brochure Capacity Expansion for Fill&Finish at Aenova Latina

    Your Partner for Conventional and Biologics Fill&FinishThe expansion of our Fill&Finish capacities is an investment in the future. Our completely new Fill&Finish suite at the Latina site enables the highest quality.

    ࡟Fully automated aseptic filling process multipurpose machine for vials/PFS products࡟Up to three additional filling lines with the chance to triple production volumes
    ࡟Capacity for 80 m vials or 180 m PFS per year
  • Brochure Animal Health

    The World’s Leading Animal Health Partner at Your SideAenova offers over 20 years of experience and 9 approved manufacturing sites. This enables us to provide excellent end-to-end services from development to packaging for a wide range of medicines for companion animals and livestock.࡟Market leading capabilities across all dosage forms 
    ࡟A strategic partner for more than 16 of the Top 20 companies
    ࡟Regulatory compliance for products marketed in over 90 countries
  • Brochure STERILE INJECTABLES

    Aenova ensures development and commercial manufacturing success. With our deep technical expertise and manufacturing know-how in a wide range of technologies, we are the one-stop CDMO for sterile injectables.࡟Wide range of capabilities including vial, ampoule and pre-filled syringe formats, lyophilized, powder filling and conventional liquid manufacturing
    ࡟Specialty production areas, including high volume, cytotoxic and small scale clinical trial material manufacturing solutions
    ࡟Regulatory compliance for products marketed worldwide, including Europe, North America and Asia
  • Brochure High Potent APIs

    There is nothing that replaces experience when it comes to HPAPI handling- from product development to commercial supply. At Aenova we offer specialized, modern infrastructure and highly qualified experts for successful development and production of highest quality HPAPI products.
    ࡟HPAPI handling up to OEB 5
    ࡟Development and commercial supply for all solid dosage forms and sterile injectables
    ࡟Oncology and immunosuppressants, hormones and lowdosed HPAPIs
  • Brochure Development Service

    At Aenova, we are proud to be your trusted partner for full-service development and technology support throughout the product lifecycle.www.aenova-group.com࡟Decades of proven experience in drug formulation and product development 
    ࡟Highly skilled scientists and engineers complemented by a dedicated project management team
    ࡟Covering all relevant dosage forms incl. HPAPI handling, inhalation products and clinical trial management
  • Brochure The Partner of Choice for Softgels

    As a market leader for softgel capsule development and manufacturing our customers benefit from our decades of experience. We dedicate our deep production process know-how and full range of technologies to get your challenging compounds to market faster.࡟On-time-delivery close to 100%
    ࡟One-stop shop from development to finished packed product supply
    ࡟State-of-the-art infrastructure ensures sustainability and business continuity
  • Technical Data Aenova Capabilities

    As a leading global contract manufacturer and development service provider with 15 production sites in Europe and the USA, we offer extensive capabilities for Steriles, Semi-solids, Solids and Packaging.
  • Brochure Corporate Brochure

    We go beyond manufacturing with a commitment to quality and reliability that is anchored in everything we do. Scientific expertise, innovative technology platforms and a strong customer focus make us the one-stop shop of choice.  ࡟ Contract development and manufacturing of all dosage forms and potency levels
    ࡟ Small to large scale production and specialized technologies 
    ࡟ Industry leading on-time delivery and quality 


    Together, let’s go beyond manufacturing to enhance patients’ lives. 
  • Brochure Aenova expands production capacities at the Tittmoning site

    On the company site of Dragenopharm Apotheker Püschl GmbH, member of the Aenova Group, a new production building is under construction.
    The production capacity of the site can thus be increased to over 10 billion tablets per year.

    The investment of about € 25 million lays the cornerstone for more than 100 new jobs and is part of further investment projects of the Aenova Group.

  • Brochure Aenova significantly expands capacity for Fill&Finish of Vaccines and Biologics

    In order to expand its fill and finish capacity for the production of Biologics and especially BSL1 and BSL2 vaccines against the SARS-CoV-2 virus, the Aenova Group is currently building a new sterile production area at its site in Latina, Italy. With an investment volume of more than 16 million euros, the focus is on a new "Fill and Finish" area for vials and prefilled syringes (PFS) with high-speed filling lines including compounding. The first line to be installed has a capacity of more than 80 million vials (glass and plastic) and over 180 million prefilled syringes per year. Aenova is also planning a phased capacity expansion of this new area with up to three additional high-speed filling lines.

Recommended products